Jashmin Patel, MD
Medical Oncology · Boise, IDNPI 1811121759
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $22 of the $34 with a category attached, or 64.4%. 3 manufacturers reported payments, led by Sanofi at 53.9% of the total. 2024 is the largest year on record at $18, 5.1 times the $4 reported in 2019.
Across 3 payments — averaging $11.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$18
- Gilead$12
- Merck$4
Across 23 payments — averaging $879.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Puma Biotechnology, Inc.$6K
- Eli Lilly$5K
- Acerta Pharma LLC$4K
- EMD Serono, Inc.$3K
- Bristol Myers Squibb$1K
- Merck$880
- plus $466 from 1 others
What the payments were for
- Food & beverage$2264%
- Education$1236%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
Too few medical oncology providers in Idahoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 77 | $1,334,057 |
| IbrancePalbociclib | 31 | $481,280 |
| LynparzaOlaparib | 17 | $251,666 |
| NinlaroIxazomib Citrate | 13 | $166,095 |
| EliquisApixaban | 24 | $17,981 |
| Exemestane | 28 | $10,835 |
| Tamoxifen Citrate | 127 | $3,478 |
| Erlotinib Hcl | 12 | $3,293 |
| Anastrozole | 170 | $2,185 |
| Dexamethasone | 59 | $1,655 |
| Hydroxyurea | 49 | $1,449 |
| Ondansetron OdtOndansetron | 66 | $1,141 |
| Letrozole | 53 | $763 |
| Acyclovir | 14 | $587 |
| Prochlorperazine Maleate | 47 | $543 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Boise
- Muhammad BegBoise$99K
- Cannon MilaniBoise$9K
- Norman ZuckermanBoise$51
- Travis WilliamsMeridian$50K
- Sushma PantLewiston$8K
- Gerardo MidenceLewiston$1K
- Daniel WilliamsLewiston$1K
- Katrina RolenLewiston$947
- Gwendoline FonebiPocatello$675
- Abeer ArainLewiston$649
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.